Triple Agonists: Revolutionizing Weight Loss or Too Much of a Good Thing?

For years, the ceiling on medical weight loss was 15%, maybe 20% if you were lucky. Now a new triple-target medication is posting average results that flirt with 30% body weight loss in clinical trials, numbers once reserved for the operating room. Holly and Jim sat down to unpack what's driving these results, and found themselves asking a question neither expected to ask in their careers: how much weight loss is actually too much?Retatrutide, the drug at the center of this episode, adds a third receptor target to the GLP-1 and GIP combination already familiar to listeners. Holly and Jim break down what this third piece brings to the table, walk through the newest published and presented trial data, and get refreshingly honest about the parts of this "medical miracle" that keep them up at night.More weight loss isn't automatically better weight loss. As these medications get more powerful, Holly and Jim argue the field needs to catch up fast on nutrition, dosing, and what "success" even means going forward. If you've been following the GLP-1 story, this episode is the plot twist you didn't see coming.Discussed on the episode:What makes this new medication a "triple agonist," and why adding a hormone best known for raising blood sugar might actually help with weight loss.The eye-opening trial results that have researchers using words like "mind-blowing" and why the number didn't plateau the way older treatments doA surprising new clinical worry that Holly never thought she'd hear herself say out loudWhy "maximum dose" might not be the right goal for most people, even though it produces the biggest numbersThe uncomfortable side effect that showed up more with this medication than with anything else on the marketWhether switching medications is a good idea if what you're currently using is already working.The philosophical question Holly and Jim now find themselves asking about appetite itself and why silencing it completely might not be a win.A hint at what's coming next in obesity treatment, involving a hormone that hasn't entered the conversation yet